Treatment of a panel of primary and established human melanoma cells with multistep increases of the BRAF inhibitor Dabrafenib (DAB), utilizing similar concentrations as in previous studies18,19, resulted in the emergence of cells with greater capability to proliferate in the presence of this compound (Supplementary Fig. 1a–h). This evidence concerns the gene BRAF and melanoma.